- Home
- MCGAW vs SCLXW Comparison
MCGAW vs SCLXW Comparison
Compare MCGAW & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCGAW | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | MCGAW | SCLXW |
|---|---|---|
| Price | $0.33 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.5K | 7.4K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $0.29 | $0.04 |
| 52 Week High | $1.50 | $0.64 |
Technical Indicators
Market Signals| Indicator | MCGAW | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 51.87 |
| Support Level | $0.30 | $0.09 |
| Resistance Level | $0.45 | $0.18 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 18.85 | 61.03 |
Price Performance
Historical ComparisonAbout MCGAW Yorkville Acquisition Corp. Warrant
Yorkville Acquisition Corp is a blank check company.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.